PUMA BIOTECHNOLOGY, INC.

PBYI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-292.0M $-276.0M $-239.3M $-142.0M $-54.7M $-74.4M $-10.2M
Depreciation & Amortization $2.8M $1.1M $776.0K $627.0K $423.0K $265.0K $11.0K
Depreciation $1.1M
Amortization $1.6M
Stock-Based Compensation $108.7M $117.3M $94.9M $39.2M $7.5M $19.6M $67.0K
Net Cash from Operating Activities $-172.5M $-141.7M $-154.5M $-77.2M $-55.0M $-44.0M $-1.8M
Investing Activities
Capital Expenditures $431.0K $4.3M $1.0M $1.1M $624.0K $253.3K
Business Acquisitions
Net Cash from Investing Activities $-15.4M $142.2M $-41.5M $-1.2M $-1.7M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $75.1M $162.4M $2.2M $129.3M $57.0M
Net Change in Cash $-112.8M $162.9M $-7.0M $-4.5M $-94.4M $84.0M $53.4M
Free Cash Flow $-172.9M $-146.0M $-155.5M $-78.3M $-55.7M $-2.1M
← Newer Page 2 of 2 Older →